ONCIMMUNE HOLDINGS PLC — Remuneration Information 2016

Nov 30, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6216Q

Oncimmune Holdings PLC

30 November 2016

30 November 2016

Oncimmune Holdings plc

("Oncimmune" or the "Company")

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 30 November 2016, options over ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") were awarded to Dan Calvo, President of Oncimmune (USA) LLC, a PDMR, as well as to certain other US staff, under the Company's Oncimmune Holdings Plc Incentive Stock Option Plan (as amended from the Oncimmune Limited Incentive Stock Option Plan that became effective 27 July 2009) as follows:

Name	Position	Number of share options awarded	Option exercise price per share (pence)	Interest in issued share capital (%)
Dan Calvo	President of Oncimmune (USA) LLC	10,151	118.5	0.02

The options are subject to the rules of the Incentive Stock Option Plan and vest in five equal annual parts, the first fifth vesting on 29 November 2017 and each year thereafter for a further four years, subject to continued employment. The options are exercisable at 118.5 pence, being the mid-market closing price of the Ordinary Shares on 29 November 2016

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny, Dominic Wilson

+44 (0) 203 829 5000

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

oncimmune@consilium-comms.com

+44 (0) 20 3709 5708

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name 

Dan Calvo

2

Reason for the notification

a)

Position/status 

President of Oncimmune (USA) LLC

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

options over Ordinary Shares - Oncimmune Holdings Plc Incentive Stock Option Plan  

ISIN GB00BYQ94H38

b)

Nature of the transaction

Grant of options over Ordinary Shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
N/A	10,151

d)

Aggregated information

Price(s)	Volume(s)
N/A	10,151

e)

Date of the transaction

30 November 2016

f)

Place of the transaction 

N/A

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHURSBRNNAAOAA